WinstonWınston
Bio Essence Corporation logo

Bio Essence Corporation

BIOE
65
Drug Manufacturers - Specialty & Generic · Healthcare
Price
$0.27
+0.00 (+0.00%)
Market Cap
$10.7M
Winston Score
65
Winston is curious
A decent business — some strong pillars, some weaker.

Share count rising — dilution

+15.1% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 33.0M (2021) → 38.0M (2025)

Bio Essence Corporation is a small specialty pharmaceutical company that makes and sells herbal and natural health products. Its core offerings include traditional Chinese medicine formulas, dietary supplements, and wellness products aimed at consumers seeking natural remedies. The company operates in the specialty and generic drug manufacturing industry, sitting at the intersection of traditional herbal medicine and modern supplement retail.

The company generates revenue primarily through product sales, likely through retail channels, distributors, and possibly direct-to-consumer sales, mostly in North America with ties to Asian herbal medicine traditions. Its gross and operating margins are unusually high for a manufacturer, suggesting low production costs relative to pricing, though the extremely high ROIC figure may reflect a very small asset base rather than a durable competitive advantage. The main risk facing Bio Essence is its very small size, which limits its ability to scale, compete with larger supplement brands, or absorb regulatory changes affecting herbal and dietary supplement products.

Winston Score History

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+902.6% YoY

YoY Growth Rate

Revenue accelerating

EPS Growth

>+1,000% YoY

YoY Growth Rate

EPS growth accelerating

R&D Spend

$0/ year

0.0% of revenue

Below sector average (18%)

Research and development spending

Insider Activity

90.5%ownership

Flat

Insiders holding steady — not selling despite ability to

Cash Position

Cash flow positive

$0 cash & investments

Quarterly Free Cash Flow

→ Burn rate stable

Company generates more cash than it spends — no dilution risk from fundraising

Revenue accelerating

Bio Essence Corporation grew revenue 903% year-over-year and the growth rate is speeding up. That's the kind of momentum growth investors look for — the question is whether margins can follow.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin
77.3%
Premium pricing power — 77.3% gross margin
Operating Margin
69.6%
Excellent — 69.6% operating margin
ROCE
N/A
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY
+485.8%
Fast-growing sales (485.8% YoY)
EPS YoY
N/A
Data not available
EPS Consistency
6/8 quarters
Earnings grew in most of the last 8 quarters

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion
175%
Turns 175% of profit into real cash
FCF Margin
82.7%
Converts sales into free cash efficiently (82.7%)

Free cash flow margin above 20%. Out of every $100 in sales, more than $20 is real cash they keep.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity
N/A
Data not available
Interest Cover
411.72x
Comfortably covers interest (411.7x)

Interest coverage above 8. Profits cover interest many times over.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)
11.4x
Attractive valuation — P/E 11.4

P/E in the normal range. Price is roughly $15 for every $1 of yearly profit.

P/E vs Forward
N/A
not available
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial